IDEXX Laboratories Inc. (IDXX)

NASDAQ: IDXX · USD

$570

+0.23 (+0.0%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-07-30 02:00 UTC. Latest published research analyzed 2026-05-13 · stale · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh IDXX analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-13

Our latest published analysis: IDXX rated Sell

IDXX is rated Sell at $533.92 versus the reconciled fair value midpoint of $335.08, implying -37.24% upside/downside. Confidence is separately disclosed at 79/100.

Fair value (mid)

$335 / share

$232 – $439

Upside to FV

-37.2%

from $570

Confidence

79/100

Moat

9/10

Read full analysis

Market cap	$42.1B
Revenue (ttm)	4.4B
Net income (ttm)	1.1B
EPS (ttm)	$13.6
Shares out	78.9M
P/E (trailing)	41.9x
P/E (forward)	32.4x
Volume	455,095
Beta	1.55
Price target	$707	+24.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4.4B
Net income (ttm): 1.1B
EPS (ttm): $13.6
P/E (trailing): 41.9x
P/E (forward): 32.4x
Market cap: $42.1B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$3.22B	$3.37B	$3.66B	$3.90B	$4.30B	+7.6%
Gross profit	$1.89B	$2.00B	$2.19B	$2.38B	$2.66B	+8.9%
Operating income	$932.0M	$898.8M	$1.10B	$1.13B	$1.36B	+9.9%
Net income	$744.8M	$679.1M	$845.0M	$887.9M	$1.06B	+9.2%
EPS (diluted)	—	$8.03	$10.06	$10.67	$13.08	+13.0%
EBITDA	$1.04B	$1.01B	$1.22B	$1.27B	$1.51B	+9.8%
R&D	$161.0M	$254.8M	$191.0M	$219.8M	$251.2M	+11.8%
SG&A	$796.4M	$850.8M	$901.9M	$1.03B	$1.05B	+7.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	41.0x	11.0x	104.3%	+6.8%	+58.6%	Sell
ABNB	Airbnb Inc.	90.8B	37.5x	7.2x	15.9%	+29.9%	+7.6%	Hold
ADBE	Adobe Inc.	104.7B	15.1x	4.2x	60.7%	+11.9%	-28.7%	Strong Buy
ABBV	AbbVie Inc.	465.2B	129.7x	7.4x	14.4%	+4.6%	+44.0%	Hold
ABT	Abbott Laboratories	186.9B	34.9x	4.0x	7.9%	+3.0%	-12.5%	Strong Buy
AMGN	Amgen Inc.	209.2B	27.0x	5.6x	19.1%	+8.1%	+32.5%	Strong Buy

All IDXX indicators

Market & fundamental data

Available fields

278

Groups with data

Currency

USD

Showing 278 of 278 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000874716
Company name	IDEXX Laboratories, Inc.
Country	United States
Country code	US
Cusip	45168D104
Employees	11,000
Employees Change	0%
Employees Change Percent	0
Enterprise value	$45.9B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
In Index	SP500, NASDAQ100
Industry	Diagnostics & Research
Industry PE	43.78
Industry PE Fwd	26.37
IPO Date	1991-06-21
Isin	US45168D1046
Last refreshed	2026-07-30
Market cap	$44.9B
Market cap category	Large-Cap
Price	$570
Price currency	USD
Rev Per Employee	404,190.45x
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2835
Symbol	IDXX
Website	https://www.idexx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.44%
EV Earnings	41.86x
EV Sales Forward	9.58x
EV/EBIT	32.61x
EV/EBITDA	29.49x
EV/FCF	42.32x
EV/Sales	10.31x
FCF yield	2.41%
Forward P/E	37.78x
P/B ratio	29.01x
P/E ratio	41.91x
P/S ratio	10.11x
PE Ratio10 Y	53.41x
PE Ratio3 Y	46.67x
PE Ratio5 Y	51.78x
PEG ratio	3.03x
PS Forward	9.39x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	31.63%
EBITDA Margin	34.97%
FCF margin	24.37%
Gross margin	62.05%
Gross Profit	$2.8B
Gross Profit Growth	14.52%
Gross Profit Growth Q	15.94%
Gross Profit Growth3 Y	10.43%
Gross Profit Growth5 Y	10.4%
Net Income	$1.1B
Net Income Growth	22.38%
Net Income Growth Q	14.74%
Net Income Growth Quarters	7%
Net Income Growth Years	3%
Net Income Growth3 Y	16.14%
Net Income Growth5 Y	10.19%
Pretax Margin	30.8%
Profit Margin	24.63%
Profit Per Employee	$99,567
Profitable Quarters	$109
Profitable Years	27
ROA	26.46
Roa5y	23.48
ROCE	67.42
ROE	72.92
Roe5y	84.36
ROIC	45.95
Roic5y	45.43

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	19.85%
Cagr15y	19.06%
Cagr1y	0.58%
Cagr20y	17.75%
Cagr3y	1.01%
Cagr5y	-3.91%
EPS Growth	25.7
EPS Growth Q	17.23
EPS Growth Quarters	7
EPS Growth Years	3
EPS Growth3 Y	17.86
EPS Growth5 Y	11.83
FCF Growth	27.81%
FCF Growth Q	12.66%
FCF Growth3 Y	33.47%
FCF Growth5 Y	10.21%
OCF Growth	24.96%
OCF Growth Q	11.89%
OCF Growth10 Y	16.71%
OCF Growth3 Y	25.5%
OCF Growth5 Y	10.2%
Revenue Growth	13.08x
Revenue Growth Q	14.26x
Revenue Growth Quarters	45x
Revenue Growth Years	28x
Revenue Growth3 Y	9.02x
Revenue Growth5 Y	9.24x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.35
Assets	$3.4B
Cash	$200.5M
Current Assets	$1.5B
Current Liabilities	$1.3B
Debt	$1.1B
Debt EBITDA	$0.71
Debt Equity	$0.71
Debt FCF	$1.02
Equity	$1.6B
Interest Coverage	36.12
Liabilities	$1.8B
Long Term Assets	$1.9B
Long Term Liabilities	$529.5M
Net Cash	$-904.9M
Net Cash By Market Cap	$-2.01
Net Debt EBITDA	$0.58
Net Debt Equity	$0.58
Net Debt FCF	$0.84
Tangible Book Value	$1B
Tangible Book Value Per Share	$13.12
WACC	12.53

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.12
Inventory Turnover	4.34
Net Working Capital	$660.5M
Quick ratio	0.69
Working Capital	$154.2M
Working Capital Turnover	$26.49

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.6%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	511.28%
1Y total return	0.58%
200-day SMA	621.2
3Y total return	3.07%
50-day SMA	556.6
50-day SMA vs 200-day SMA	50under200
5Y total return	-18.09%
All Time High	770
All Time High Change	-26%
All Time High Date	2025-11-26
All Time Low	0.84
All Time Low Change	67,424.29%
All Time Low Date	1991-08-19
ATR	17.46
Beta	1.55
Beta1y	0.97
Beta2y	0.81
Ch YTD	-15.78
High	575.2
High52	770
High52 Date	2025-11-26
High52ch	-26%
Low	562.2
Low52	518.6
Low52 Date	2026-06-30
Low52ch	9.88%
Ma50ch	2.37%
Price vs 200-day SMA	-8.27%
RSI	55.45
RSI Monthly	51.67
RSI Weekly	46.55
Sharpe ratio	0.12x
Sortino ratio	0.4
Total Return	2.6%
Tr YTD	-15.78
Tr15y	1,270.13%
Tr1m	3.31%
Tr1w	4.55%
Tr3m	0.26%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	15
Analyst Count Top	4
Analyst Price Target Top	$713
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$3.94
Earnings EPS Estimate Growth	12.57
Earnings Revenue Estimate	1,199,865,256x
Earnings Revenue Estimate Growth	8.15x
Operating Income	$1.4B
Operating Income Growth	14.85
Operating Income Growth Q	11.38
Operating Income Growth3 Y	14.49
Operating Income Growth5 Y	11.86
Operating margin	31.42
Price target	$707
Price Target Change	$24.09
Price Target Change Top	$25.05

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	78,583,363%
Float Percent	99.62%
Net Borrowing	32,115,000
Shares Insiders	0.26%
Shares Institutions	94.77%
Shares Out	78,882,997
Shares Qo Q	-0.4%
Shares Yo Y	-2.6%
Short Float	2.67%
Short Ratio	2.84
Short Shares	2.66

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$1B
Adjusted OCF	1,148,353,000
Average Volume	596,829.65x
Bv Per Share	19.64
CAPEX	$-126.6M
Ch10y	511.3
Ch15y	1,270.1
Ch1m	3.31
Ch1w	4.55
Ch1y	0.58
Ch20y	2,525.3
Ch3m	0.26
Ch3y	3.07
Ch5y	-18.09
Ch6m	-17.15
Change	0.04%
Change From Open	0.38
Close	569.5
Days Gap	-0.34
Depreciation Amortization	148,803,000
Dollar Volume	259,299,478.2
Earnings Date	2026-08-04
Earnings Time	bmo
EBIT	$1.4B
EBITDA	$1.6B
EPS	$13.59
F Score	7
FCF	$1.1B
FCF EV Yield	2.36x
FCF Per Share	$13.73
Financing CF	-1,046,073,000
Fiscal Year End	December
Founded	1,983
Goodwill	412,104,000
Graham Number	77.50207
Graham Upside	-86.4
Income Tax	$274.3M
Investing CF	-140,173,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Date	2015-06-16
Last Split Type	Forward
Last10k Filing Date	2026-02-20
Lynch Fair Value	$139
Lynch Upside	-75.69
Ma150	599
Ma150ch	-4.88%
Ma20	557.7
Ma20ch	2.16%
Net CF	36,558,000
Next Earnings Date	2026-08-04
Open	567.6
Optionable	Yes
P FCF Ratio	41.48
P FCF Ratio SBC	43.99
P OCF Ratio	37.14
P OCF Ratio SBC	39.14
Position In Range	58.2
Post Close	569.8
Postmarket Change Percent	0.22
Postmarket Price	$571
Ppne	861,777,000
Price Date	2026-07-29
Price EBITDA	$28.91
Ptbv Ratio	43.25
Relative Volume	0.76x
Revenue	4,446,095,000x
SBC By Revenue	1.39x
Share Based Comp	61,738,000
Tax By Revenue	6.17x
Tax Rate	20.03%
Tr20y	2,525.37%
Tr6m	-17.15%
Us State	Maine
Volume	455,095
Z Score	21.31

Frequently asked questions

About this IDXX report

What is the latest published IDXX stock rating?

IDEXX Laboratories Inc. is shown with sell in the latest published report, analyzed 2026-05-13. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full IDXX analysis?

The full latest published report, analyzed 2026-05-13, lives at /stocks/IDXX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for IDXX?

The latest published report analyzed 2026-05-13 frames IDXX around USD 232 to USD 439. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the IDXX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-13). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

IDEXX Laboratories Inc. (IDXX)

Coverage state: Latest published research available

Generate a fresh IDXX analysis

Our latest published analysis: IDXX rated Sell

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · IDXX

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All IDXX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on IDXX

Frequently asked questions